ENTITY
Hutchmed China Ltd

Hutchmed China Ltd (13 HK)

166
Analysis
IndustrialsHong Kong
HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.
more
Refresh
12 Mar 2024 08:55

Hutchmed China Ltd (13.HK/​​HCM.US) - High Growth Is Expected from 2024 to 2026

HUTCHMED will enter a period of accelerated growth in product revenue based on major catalysts in 2024 to 2026. Global sales of fruquintinib will...

Logo
337 Views
Share
01 Mar 2024 19:54Broker

Hutchmed (13 HK) – A Fruitful 2024 on the Way

Including US$312mn upfront and milestone payments from Takeda, HCM’s consolidated revenues from oncology/immunology reached US$529mn in FY23

Logo
331 Views
Share
20 Feb 2024 08:55

Hutchmed China Ltd (13.HK/​​HCM.US) - 2023 Results Preview and Catalysts in 2024

HUTCHMED has entered a harvest period.Product revenue would grow rapidly in the next two years, with promising catalysts head.Together with...

Logo
300 Views
Share
20 Dec 2023 08:55

Hutchmed China Ltd (13.HK/​HCM.US) - A Valuable Option in the Portfolio

Despite market's lackluster response to fruquintinib’s FDA approval, we're optimistic about HUTCHMED’s outlook.Rich cash flow/future catalysts make...

Logo
428 Views
Share
10 Nov 2023 19:31Broker

Hutchmed (13 HK) – Big Milestone Achieved with Fruquintinib Successfully Approved by US FDA

The approval was based on the Ph3 MRCT FRESCO-2 (18% patients enrolled from the US) as well as the China FRESCO trial, implying the recognition of...

Logo
372 Views
Share
x